Sector News

As Allergan shares languish, Icahn unloads most of his $700M stake

November 16, 2016
Life sciences

When activist investor Carl Icahn picked up a big stake in Allergan in May, it was one of his biggest buys of the year—and far from a move against current management, as is his wont. It was an endorsement of CEO Brent Saunders.

Now, Icahn has cashed out.

At the end of June, according to securities filings cited by The Wall Street Journal, Icahn had $700 million socked into Allergan shares. By the end of September, that stake had dwindled to just $98 million.

Saunders has enjoyed Icahn’s confidence before. During a proxy fight with Forest Laboratories’ board several years ago, Icahn and his supporters helped bring in Saunders to take over from longtime chief Howard Solomon.

When Forest sold soon after, shareholders reaped “massive gains,” Icahn said earlier this year—including, of course, Icahn himself. Apparently, Icahn figured he’d see the same sort of boon from Allergan under Saunders’ leadership.

Unfortunately, Allergan doesn’t have a megamerger partner on tap to deliver quick M&A gains, now that Pfizer and its $160 billion takeover is off the table. Rumors now put Allergan in the buyers’ seat for deals big and small. And the company’s shares haven’t performed at their best this year. Starting the year trading at $300-plus, Allergan closed at $202 Monday.

After word of Icahn’s big investment surfaced in May–when shares stood at $253—the company’s stock has mostly traded below that number, and have declined markedly since late October.

It didn’t help, of course, that third-quarter results, reported Nov. 2, didn’t come up to standard. Defending the numbers, Saunders pointed to growth for most of Allergan’s “top-level products,” some of which turned in double-digit increases. “It’s a very good picture to have so many products growing so strongly,” Saunders said.

“The results are far from great. The question now is whether this is an aberration or a new trend line,” Bernstein analyst Ronny Gal wrote in a note to clients after earnings were released.

Does Icahn’s selloff mean he feels differently about Saunders these days? Not necessarily; Allergan has some specific challenges in the short term, including generic competition for a big seller, the Parkinson’s disease therapy Namenda XR. It has new competition for its big-selling eye drug Restasis. Plus, the pipeline deals Saunders has made lately are longer-term payoffs, if potentially large ones.

So, Icahn just might not want to wait around for returns as Allergan works its way forward. Then again, he might not want to take the chance that those long-term hopes don’t pay off.

Gal seems to think that Allergan will soon be on its way up, and that some critical evaluations of its business don’t hold up on analysis. The emphasis is on the decline in older products, he said in a Tuesday note, and that’s too limited: “[T]he market is ignoring a material mix-shift in earnings toward high quality durable products.”

“Allergan will gradually transition to growth as it overcomes the loss of Namenda XR and decline of Restasis,” he predicted in his Q3 note. “[T]his quarter will likely serve to set the floor on this transition.”

By Tracy Staton

Source: Fierce Pharma

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach